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Objective: Dysphoria and depression have been cited as side effects of the opioid antagonist naltrexone. We aimed to assess whether
depressive symptoms are a clinically relevant side effect in a population receiving naltrexone as a treatment for opioid dependence.
Methods: We carried out a randomized controlled, open-label trial comparing rapid opiate detoxification under anesthesia and naltrex-
one treatment with continued methadone maintenance at the Alcohol and Drug Service, Royal Brisbane and Women’s Hospital, Bris-
bane, Australia. The study subjects were patients stabilized on methadone maintenance treatment for heroin dependence who wished to
transfer to naltrexone treatment. The Beck Depression Inventory, State–Trait Anxiety Inventory and Opiate Treatment Index subscales
for heroin use and social functioning were used at baseline and follow-up assessments at 1, 2, 3 and 6 months. Results: Forty-two par-
ticipants were allocated to receive naltrexone treatment, whereas 38 continued methadone maintenance as the control condition. Partici-
pants who received naltrexone did not exhibit worsening of depressive symptoms. In participants attending all follow-up assessments,
there was a trend for those receiving naltrexone to exhibit an improvement in depression over time compared with the control group. Par-
ticipants who were adherent to naltrexone treatment exhibited fewer depressive symptoms than those who were nonadherent. Conclu-
sions: These results suggest that depression need not be considered a common adverse effect of naltrexone treatment or a treatment
contraindication and that engaging with or adhering to naltrexone treatment may be associated with fewer depressive symptoms.
Objectif : On a mentionné la dysphorie et la dépression comme effets secondaires du naltrexone, antagoniste des opiacés. Nous
voulions déterminer si les symptômes dépressifs constituent un effet secondaire pertinent sur le plan clinique dans une population
prenant du naltrexone comme traitement contre une accoutumance aux opiacés. Méthodes : Au service de traitement de l’alcoolisme et
des toxicomanies du Royal Brisbane and Women’s Hospital, à Brisbane, en Australie, nous avons procédé à un essai contrôlé ran-
domisé ouvert pour comparer une détoxification rapide des opiacés sous anesthésie et un traitement au naltrexone conjugué à un traite-
ment de maintien soutenu à la méthadone. Les sujets à l’étude étaient des patients stabilisés par un traitement de maintien à la
méthadone pour une dépendance à l’héroïne et qui voulaient passer au traitement au naltrexone. Nous avons utilisé l’inventaire de dé-
pression de Beck, le questionnaire sur l’anxiété chronique et réactionnelle de State–Trait et les sous-échelles de l’indice des traitements
contre les opiacés pour la consommation d’héroïne et le fonctionnement social afin d’effectuer des évaluations de référence et de suivi à
1, 2, 3 et 6 mois. Résultats : On a désigné 42 participants qui suivraient le traitement au naltrexone tandis que 38 sont demeurés sur le
maintien à la méthadone comme condition témoin. Les symptômes dépressifs ne se sont pas aggravés chez les participants qui ont pris
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Introduction
Naltrexone is a competitive mu opioid receptor antagonist
used in the treatment of opioid dependence. Because its affin-
ity for mu receptors is greater than that of heroin and other
opioid agonists, naltrexone is able to block the effects of other
opioids.1 This may lead to extinguishing of drug-taking be-
haviour and may reduce opiate craving.2–4 Furthermore, ad-
ministration of naltrexone to an opioid-dependent individual
will trigger a withdrawal syndrome. This is the rationale for
rapid opiate detoxification, a procedure often undertaken be-
fore initiating treatment with naltrexone, often in conjunction
with sedation or anesthesia.5–9
There have been claims of good treatment outcomes asso-
ciated with naltrexone. For example, some studies report that
naltrexone treatment produces a reduction in heroin use or
reductions in reincarcerations compared with placebo or
other treatments.10,11 However, many reports also describe
poor retention rates for individuals undergoing naltrexone
treatment12–14 or low rates of uptake into naltrexone
treatment,15 which may undermine its potential benefits.
Depression and dysphoria have been cited as adverse ef-
fects of naltrexone. The presence of, or concern about, these
adverse effects may contribute to poor treatment uptake or
retention. One of the early reports linking naltrexone with
depression arose from a study of volunteers with no history
of opioid or other drug use.16 Compared with placebo, a sin-
gle 50-mg dose of naltrexone led to a range of unpleasant
symptoms, including dysphoria. Since that time, experimen-
tal studies have described depression or dysphoria associated
with the use of naltrexone in healthy volunteers17 or opioid-
free former addicts.18
There is conflicting evidence as to whether depressive
symptoms or dysphoria are clinically important adverse ef-
fects in patients receiving naltrexone treatment. In an uncon-
trolled cohort study, Miotto and colleagues19 reported that 81
patients who were receiving naltrexone for opioid depen-
dence exhibited higher than expected rates of overdose and
suicide. Despite this, depressive symptoms improved during
the course of treatment. A controlled trial of naltrexone in an
alcohol-dependent population20 reported that although de-
pressive symptoms improved in naltrexone-treated and
placebo-treated patients over time, a significantly higher pro-
portion of naltrexone-treated patients had elevated depres-
sion scores at study completion compared with those receiv-
ing placebo. However, it was not established whether this
difference reflected a side effect of naltrexone or greater attri-
tion of depressed subjects from the placebo group. Few con-
trolled studies have examined depressive symptoms in heroin
users receiving naltrexone treatment for opiate dependence.
The aim of this study was to investigate the impact of nal-
trexone treatment on depressive symptoms in a controlled
clinical study. We hypothesized that subjects taking naltrex-
one would experience an increase in depressive symptoms
after initiation of naltrexone treatment and that the presence
of depressive symptoms would be associated with a poorer
treatment outcome.
Methods
This study is based on the findings of a larger research un-
dertaking comparing rapid opiate detoxification and naltrex-
one with methadone maintenance as a treatment for opioid
dependence. Ethics approval was obtained from the Human
Research Ethics Committee of the Royal Brisbane and
Women’s Hospital. Recruitment and follow-up took place be-
tween March 1999 and December 2002.
We recruited 80 opioid-dependent individuals who were
receiving methadone maintenance treatment who had ex-
pressed an interest in transferring to naltrexone treatment.
Participants were recruited by clinical referral or self-referral
through advertising in various alcohol and drug services
throughout Brisbane and other relevant services. Inclusion
criteria were the following: age between 18 and 60 years; a
history of methadone maintenance for at least 1 year; at least
2 unsuccessful attempts to cease methadone maintenance; a
stable residence (no more than 2 changes of residence in the
previous 6 months); and the presence of a non-drug-using
support person who would supervise naltrexone administra-
tion on a daily basis. Exclusion criteria included symptomatic
chronic liver disease, active psychosis, severe sedative depen-
dence (> 40 mg diazepam equivalents per day) or depen-
dence on alcohol, amphetamines or cocaine. Although a his-
tory of a depressive disorder or the use of antidepressants
were not a basis for exclusion, potential participants who had
current severe major depressive disorder or were considered
to be at high risk of suicide were excluded from the study.
This was ascertained by a thorough psychiatric assessment.
After telephone screening, potentially eligible subjects
were invited to attend the clinic for assessment. After they
had been provided with verbal and written information
about the study (including the patient information sheet), eli-
gible participants provided written informed consent. Subse-
quent assessment included a physical examination, blood
tests (liver function tests, hepatitis B and C, and HIV serol-
ogy) and a psychiatric assessment.
Randomization took place after provision of informed con-
sent and was carried out by an independent research facility
le naltrexone. Parmi ceux qui se sont présentés à toutes les évaluations de suivi, ceux qui prenaient le naltrexone avaient tendance à
montrer une amélioration de la dépression au fil du temps, comparativement aux sujets du groupe témoin. Les participants qui ont
observé fidèlement le traitement au naltrexone montraient moins de symptômes dépressifs que ceux qui ne l’ont pas observé. Conclu-
sions : Ces résultats indiquent qu’il ne faut pas considérer la dépression comme un effet indésirable courant du traitement au naltrexone
ou comme une contre-indication au traitement, et que l’on peut établir un lien entre l’engagement avec le traitement au naltrexone ou
l’observation fidèle du traitement au naltrexone et des symptômes dépressifs moins nombreux.
(National Health and Medical Research Council Clinical Tri-
als Centre). The research team provided participant IDs to
the facility via a central telephone service and were then pro-
vided with details of allocation outcome. Subjects were
evenly randomly allocated to receive either rapid opioid
detoxification under anesthesia (RODA) followed by naltrex-
one maintenance for up to 12 months or continued
methadone maintenance for 6 months. This study was not
blinded, and researchers, clinicians and participants were
aware of what intervention participants were receiving.
The treatment group continued methadone maintenance
until the day of admission. On admission, all patients re-
ceived a detoxification regime including clonidine and di-
azepam for 36 hours. Patients then underwent general anes-
thesia for 4 hours. Following induction of anesthesia and
intubation, naltrexone (50 mg) was administered as a slurry
via a nasogastric tube; a second dose (50 mg) was adminis-
tered 2 hours later. Clonidine, octreotide and ondansetron
were also administered during the procedure to suppress
withdrawal manifestations. Patients were monitored
overnight and were typically discharged the following day.
Patients received 2 further 50-mg oral doses of naltrexone on
the evening of the procedure and on the day of discharge.
Thereafter, patients received naltrexone, 50 mg administered
orally, daily for up to 12 months. Daily dosing was super-
vised by a non-drug-using support person, who was typi-
cally a parent. Ongoing supportive psychosocial care was
provided by the clinical team throughout treatment; how-
ever, formal psychotherapy was not provided.
Participants assigned to the control condition were to con-
tinue methadone maintenance for a further 6 months.
Methadone treatment was provided by the participants’ ex-
isting clinic; during this time, no additional treatment was
provided by the research team. All participants assigned to
the control group were offered the opportunity to undergo
RODA and receive naltrexone treatment after 6 months in the
control condition.
Participants underwent follow-up assessments at 1, 2, 3 and
6 months after baseline. The following instruments were used.
The Beck Depression Inventory (BDI)21 is a 21-item self-report
questionnaire with item scores ranging from 0 to 3 and a total
score of 0–63. It has been verified as a reliable and valid screen-
ing instrument to detect intensity of depression in a variety of
populations and has also been employed to measure treatment
response when used in a pretest and post-test study design.22
In order to control for any potential influence of anxiety on
depression measures, anxiety was measured using the
State–Trait Anxiety Inventory (STAI).23 The STAI is a 40-item
self-report questionnaire used to measure both current anxi-
ety or state (20 items) and anxiety as a more enduring stable
personality characteristic or trait (20 items). In this study, we
used only the state component of the instrument.
The Opiate Treatment Index (OTI)24 includes subscales per-
taining to drug use and social functioning. Primary drug use
outcomes were measured by recent frequency (number of days
that heroin was used in the previous 28 days) and the monetary
expenditure (Australian dollars spent on heroin in the previous
28 days). The Social Functioning subscale contains items reflect-
ing overall social stability and support and also incorporates a
measure of involvement in drug subculture.
Craving for heroin was assessed using 2 questions on fre-
quency of thoughts about heroin (How frequently do you
have thoughts about heroin?) and desire or compulsion to
use heroin (How frequently do you have the desire to use
heroin?). Each was assessed on a self-report, 6-point Likert
scale (0 = rarely or never, 5 = very often).
Medication adherence was assessed fortnightly using self-
report and corroborated by a report from a non-drug-using
support person who was engaged to supervise naltrexone
administration.
The sample size was calculated on the basis of the primary
outcome measure of reduced heroin use in those allocated to
RODA–naltrexone compared with those continuing on
methadone, using an expected effect size of 0.4 standard de-
viation (SD) units, a power of 0.8 and an α of 0.05 to reject
the null hypothesis. The expected attrition rate in both
groups over 6 months was 30%.25–27 With these parameters,
the required sample size for each treatment group was de-
termined to be 37.
Treatment effects data were analyzed using a 2-way fixed-
effects repeated-measures analysis of variance (ANOVA)
with the between-groups factor being treatment (naltrexone
or methadone) and the within-groups factor being time (0, 1,
2, 3 and 6 months). Partial η2 values (ηp2) were calculated to
determine effect size. The analysis examined overall changes
over time and changes over time between groups (interaction
of time and treatment). This was conducted on both sets of
data elicited from those individuals for whom we had com-
plete data and also on all randomly allocated subjects using
an intention-to-treat analysis with missing data imputed
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Table 1: Baseline characteristics of participants*
Participant group; mean (and SD)†
Characteristic
Naltrexone,
n = 42
Methadone,
n = 38
Male, no. (and %) 23 (55) 21 (55)
Age, yr 31.0x (6.6) 31.0x (9.1)
In full-time employment,
no. (and %)
11 (26) 10 (26)
No. of times a participant has
started
Inpatient detoxification 2.1x (3.0) 0.9x (1.3)
Outpatient detoxification 2.4x (3.6) 2.7x (3.7)
Methadone maintenance 2.7x (3.0) 2.2x (1.4)
Current methadone dose, mg 41.8 (23.2) 49.3 (31.9)
Age of onset of
Heroin use, yr 20.1x (4.5) 20.6x (5.1)
Heroin dependence, yr 22.0x (4.4) 23.2x (6.3)
No. of days heroin was used
in the previous 28 days
6.2x (8.4) 4.1x (7.2)
Cost of typical day’s use, A$ 72.7 (77.6) 49.2 (52.7)
BDI score 12.1x (7.7) 11.7 (10.2)
Participants who used
antidepressants, no. (and %)
4 (9.5) 1 (2.6)
BDI = Beck Depression Inventory; SD = standard deviation.
*p > 0.05 for all comparisons between treatment groups.
†Unless otherwise indicated.
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using the last observation carried forward. As the purpose of
this study was to assess the incidence of a potential adverse
effect of medication, the relation between treatment adher-
ence and depression scores was examined. Subjects were
classified as treatment adherent if they received at least 80%
of their naltrexone or methadone throughout the first
3 months of the study. The first 3-month time period was se-
lected post hoc for the adherence analysis, because early
treatment represents the most clinically important period for
assessment of drug-related adverse effects, and very few par-
ticipants were adherent to naltrexone for the entire 6-month
period, making group comparisons difficult. Using 1-way
ANOVA, depression scores were compared between adher-
ent and nonadherent participants, using both existing and
imputed data at 1-month, 2-month and 3-month follow-up
assessments. Effect sizes were calculated using η2. Relations
between continuous variables were analyzed using bivariate
correlations. For normally distributed data, Pearson’s prod-
uct-moment correlation coefficient, r, was used; Spearman’s
rank-order correlation coefficient, rho, was used for data that
did not meet normality assumptions. Group differences at
baseline were evaluated using independent samples t tests
for continuous variables and χ2 tests for categorical variables.
In all analyses, the level of significance used to reject the null
hypothesis was an α of 0.05.
Results
Of the 80 participants, 42 were randomly allocated to receive
RODA–naltrexone; 38 were randomly allocated to the control
group and continued methadone maintenance. Demographic
and baseline characteristics for each group are detailed in
Table 1. No baseline differences were detected between sub-
jects receiving RODA and naltrexone treatment and those in
the control group. The primary findings of this study are re-
ported elsewhere.28 In those receiving RODA and naltrexone
treatment, 74% were engaged in treatment at 10 days, and
52% remained engaged in treatment at 3 months. Participant
flow through the study is outlined in Figure 1.
The mean BDI score at baseline for all participants was 11.9
(SD 8.9, range 0–37); 16% of participants had a score of 21 or
greater (the accepted cut-off for moderate-to-severe depres-
sion29). BDI scores at baseline were not related to demo-
graphic variables such as sex, age, education or employment.
Baseline BDI was also unrelated to drug use variables, in-
cluding age of onset of heroin use or number of days heroin
was used in the previous month. There was a significant pos-
itive relation between baseline depressive symptoms and
baseline heroin craving measured as thoughts about heroin
(Spearman r = 0.49, p = 0.010), but not when measured as de-
sire to use heroin (Spearman r = 0.28, p = 0.16).
6-month follow-up
Attended n = 13
1-month follow-up
Attended n = 28
Missed n = 2
2-month follow-up
Attended n = 19
Missed n = 6
3-month follow-up
Attended n = 21
Missed n = 2
Allocated to naltrexone
group
n = 42
12 lost to
follow-up
2 lost to
follow-up
5 lost to
follow-up
10 lost to
follow-up
6-month follow-up
Attended n = 28
1-month follow-up
Attended n = 14
Missed n = 17
2-month follow-up
Attended n = 16
Missed n = 15
3-month follow-up
Attended n = 26
Missed n = 5
Allocated to control
group
n = 38
7 lost to
follow-up
0 lost to
follow-up
0 lost to
follow-up
3 lost to
follow-up
Subjects enrolled in the study
n = 80
R
Fig. 1: Engagement in study protocol as represented by attendance at follow-up assess-
ments throughout the study.
Treatment effects on depression and anxiety
In the subset of subjects who attended all follow-up assess-
ments (n = 17), no worsening of depression scores was ob-
served. Indeed, there was a trend for subjects receiving nal-
trexone to exhibit an improvement in depression (F1,16 = 2.84,
p = 0.07, ηp2 = 0.49) over time compared with those on
methadone maintenance. This effect was primarily the result
of differences between treatment groups at 2 and 3 months;
both treatment groups had similar values at 6 months. Par-
ticipants who attended all follow-up assessments were fully
compliant with treatment, except for the 2 receiving nal-
trexone who ceased naltrexone shortly before the 6-month
follow-up. When analyzed on an intention-to-treat basis,
there were no increases or other changes in BDI scores over
time in the whole sample (F1,74 = 0.36, p = 0.83, ηp2 = 0.02) and
no difference between treatment groups (F1,74 = 1.30, p = 0.28,
ηp2 = 0.07). BDI scores are detailed in Table 2. No difference
in the use of antidepressants between treatment groups was
detected (naltrexone n = 16, methadone maintenance treat-
ment n = 7), although this nonsignificant finding may have
been influenced by data on antidepressant use being avail-
able for only 36% of participants.
When the impact of treatment adherence on depressive
symptoms was examined, the severity of symptoms was
consistently lower among participants who were adherent to
naltrexone treatment compared with those who were nonad-
herent to naltrexone treatment. This was statistically signifi-
cant at month 2 (F = 11.3, p = 0.002, η2 = 0.22), month 3 
(F = 5.74, p = 0.021, η2 = 0.13) and month 6 (F = 7.01, p =
0.012, η2 = 0.15), with a trend at month 1 (F = 3.91, p = 0.06,
η2 = 0.09) using imputed data. There were no significant
baseline differences in depressive symptoms between those
adherent and nonadherent to naltrexone. There were no sig-
nificant differences in depression scores between those ad-
herent and nonadherent to methadone treatment (Table 3).
Treatment effects on anxiety were also examined. Using
the intention-to-treat analysis, we observed a significant in-
crease in anxiety symptoms in all subjects over time (F1,74 =
2.72, p = 0.037, ηp2 = 0.13). There was also a trend suggesting
differences between treatment groups (F1,74 = 2.27, p = 0.07,
ηp2 = 0.11). This was mainly because of an increase in symp-
toms in the naltrexone group between baseline and the 1-
month assessment, whereas the control group exhibited an
Dean et al
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Table 3: Beck Depression Inventory (BDI) scores for participants adherent and
nonadherent to treatment
Group; BDI scores, using imputed data, mean (SD) [and 95% CI]*
Participant
group, follow-up Fully adherent Nonadherent p value
Naltrexone n = 15 n = 27
Baseline 10.1 (7.6) [5.9–14.3] 13.2x (7.7) [10.2–16.3] 0.22
1 mo x9.7 (7.1) [5.8–13.7] 15.7 (10.4) [11.6–19.8] 0.06
2 mo x6.3 (4.4) [3.8–8.7] 15.3x (9.8) [11.4–19.2] 0.002
3 mo x7.5 (6.2) [4.1–11.0] 14.1x (9.5) [10.3–17.9] 0.021
6 mo x8.5 (7.0) [4.7–12.4] 15.5x (8.7) [12.0–18.9] 0.012
Methadone n = 23 n = 15
Baseline 9.8 (9.6) 14.6 (10.7) 0.17
1 mo 10.3 (9.5) 15.1 (10.6) 0.16
2 mo 11.0 (9.1) 14.6 (10.7) 0.28
3 mo 11.2 (9.1) 15.4 (10.9) 0.20
6 mo 10.4 (7.5) 13.2x (9.8) 0.32
CI = confidence interval; NS = not significant; SD = standard deviation.
*Unless otherwise indicated.
Table 2: Beck Depression Inventory (BDI) scores of study subjects
Participant group; mean BDI score
(and SD)*
Follow-up assessment of BDI Naltrexone Methadone
Subjects who attended all
assessments
n = 9 n = 8
Baseline 12.7x (8.5) 11.1x (8.3)
1 mo 11.1x (8.2) 12.0x (7.7)
2 mo 5.0x (4.7) 12.0 (10.1)
3 mo 6.0x (5.0) 9.8x (9.9)
6 mo 9.4x (7.3) 9.0x (8.4)
Existing data, without imputation
n = 42 n = 38Baseline
SE 2.0, CI –3.6 to 4.5 12.1x (7.7) 11.7 (10.2)
n = 28 n = 141 mo
SE 2.3, CI –2.9 to 6.1 13.3 (10.7) 12.0x (8.5)
n = 19 n = 162 mo
SE 2.2, CI –4.6 to 4.1 9.2x (9.2) 12.5x (8.5)
n = 21 n = 263 mo
SE 2.2, CI –5.0 to 3.7 9.3x (8.7) 12.1x (9.3)
n = 13 n = 286 mo
SE 2.0, CI –2.65 to 5.4 10.6x (7.7) 11.6x (8.4)
Intention to treat,† n = 80 n = 42 n = 38
Baseline 12.1x (7.7) 11.7 (10.2)
1 mo 13.6x (9.7) 12.0 (10.1)
2 mo 12.1x (9.3) 12.3x (9.9)
3 mo 11.8x (9.0) 12.4 (10.2)
6 mo 13.0x (8.7) 11.6x (8.8)
CI = confidence interval; SD = standard deviation; SE = standard error.
*Unless otherwise indicated.
†Intention-to-treat analysis incorporates imputation of missing data using last
observation carried forward.
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increase in anxiety symptoms toward the end of the 6-month
period (Table 4).
Changes in depression and anxiety — relation with 
treatment outcomes
Baseline depressive symptoms, as measured by the BDI,
did not influence short-term detoxification outcomes in-
cluding completion of detoxification (t = –1.36, p = 0.18) or
abstinence during the first 7 days (t = 1.47, p = 0.15). Simi-
larly, baseline anxiety did not predict completion of detoxi-
fication (t = –0.85, p = 0.40) or abstinence during the first
7 days (t = 0.27, p = 0.79).
There were no differences in baseline BDI scores or demo-
graphic variables between those subjects who attended all
follow-up assessments and those who did not. BDI scores at a
particular assessment did not predict attendance at the subse-
quent assessment. Those with higher anxiety scores at
2 months were less likely to attend for follow-up at 3 months
(t = 2.52, p = 0.017) and 6 months (t = 2.05, p = 0.049). Anxiety
at other time points had no relation with attendance.
There were no observed relations between changes in de-
pression or anxiety scores and changes in heroin-using
days or expenditure on heroin use over corresponding time
periods.
There were significant relations between BDI scores and
thoughts about heroin when measured at the same time
point, where higher levels of depression correlated with
more frequent thoughts about heroin. These relations were
observed at 1-month (Spearman r = 0.51, p = 0.006), 
3-month (Spearman r = 0.46, p = 0.003) and 6-month (Spear-
man r = 0.50, p = 0.003) assessments. Higher levels of de-
pression also correlated with a greater desire to use heroin
at 1-month (Spearman r = 0.59, p = 0.002), 3-month (Spear-
man r = 0.48, p = 0.002) and 6-month (Spearman r = 0.37,
p = 0.034) assessments. Relations were observed between
anxiety symptoms and thoughts of using heroin at 1-month
(Spearman r = 0.56, p = 0.003) and 3-month (Spearman 
r = 0.38, p = 0.020) assessments but not at 6 months (Spear-
man r = 0.30, p = 0.09). Similarly, higher anxiety symptoms
correlated with a greater desire to use heroin at 1-month
(Spearman r = 0.63, p = 0.001) and 3-month (Spearman 
r = 0.37, p = 0.021) assessments but not at 6 months (Spear-
man r = 0.13, p = 0.46).
Improvements in BDI between 0 and 6 months correlated
with improvements in social functioning over the same pe-
riod as measured by the OTI (Pearson r = 0.38, p = 0.039).
Changes in anxiety were unrelated to changes in social func-
tioning (Pearson r = 0.13, p = 0.51).
Discussion
These findings describe the presence of depressive symp-
toms during naltrexone treatment for opiate dependence in
the context of a randomized controlled trial. In contrast to
our initial hypothesis, naltrexone treatment did not lead to
an increase in depressive symptoms. Indeed, when we ex-
amined the subgroup of participants who were fully en-
gaged in treatment, there was a trend for depressive symp-
toms to be lower while on naltrexone compared with
continued methadone maintenance. In addition, partici-
pants who were adherent to naltrexone treatment had
fewer depressive symptoms than those not adherent to nal-
trexone treatment.
These findings are in contrast to previous experimental
studies that report dysphoria or depression occurring after
naltrexone use.16–18 One possible explanation for this discrep-
ancy is that the improvement in depressive symptoms ob-
served in fully engaged or adherent subjects may reflect the
attrition of those who experienced dysphoria or depressive
symptoms after initiation of naltrexone. Although this possi-
bility cannot be ruled out, changes in depression scores failed
to predict attendance or compliance at subsequent assess-
ments. Furthermore, we believe that fewer depressive symp-
toms in those who were adherent to naltrexone treatment in-
dicates that depressive symptoms are not a general
consequence of naltrexone exposure. The relation between de-
pressive symptoms and poor adherence to naltrexone may be
bidirectional: improving either depressive symptoms or ad-
herence may assist in the improvement of the other.
Our findings are consistent with more recent data that re-
port small improvements in mood associated with naltrex-
one treatment.19,30,31 Rea and colleagues30 compared standard
doses of naltrexone (50 mg daily) with low (0.5 mg) and
Table 4: State Anxiety (STAI) scores of study subjects
Participant group; mean STAI
score (and SD)*
Follow-up assessment of STAI Naltrexone Methadone
Subjects who attended all
assessments
n = 9 n = 8
Baseline 34.9 (14.7) 38.1 (14.4)
1 mo 37.9 (17.2) 38.6 (17.1)
2 mo 29.0 (12.2) 38.3 (16.1)
3 mo 34.6x (9.0) 41.1 (12.5)
6 mo 34.8 (11.7) 37.6 (12.9)
Existing data, without imputation
Baseline n = 42 n = 38
35.7 (12.0) 37.6 (12.4)
1 mo n = 28 n = 14
42.0 (15.6) 36.5 (15.7)
2 mo n = 19 n = 16
35.6 (14.9) 40.4 (14.7)
3 mo n = 21 n = 26
38.1 (10.8) 41.9 (10.4)
6 mo n = 13 n = 28
35.8 (11.8) 38.8 (11.8)
Intention to treat,† n = 80 n = 42 n = 38
Baseline 35.7 (12.0) 37.6 (12.4)
1 mo 40.3 (14.3) 37.4 (13.1)
2 mo 37.4 (13.7) 38.3 (13.0)
3 mo 39.1 (11.7) 40.8 (11.6)
6 mo 39.1 (12.6) 39.0 (12.6)
Note: SD = standard deviation.
*Unless indicated otherwise.
†Intention-to-treat analysis incorporates imputation of missing data using last
observation carried forward.
ultra-low (0.05 mg) doses. They report a modest reduction in
depressive symptoms in those subjects attending follow-up
assessments, regardless of what dose they were receiving. A
large naturalistic study of alcohol dependence reported that
only 1.4% (7/500) of patients receiving naltrexone reported
treatment-emergent depression compared with 1.7% in a ref-
erence group not receiving naltrexone.32 A recent review of
clinical studies33 concluded that naltrexone treatment does
not produce dysphoria as a serious side effect.
It is difficult to engage heroin users in naltrexone treat-
ment, and adherence rates are typically poor. As such, these
current findings may be generalized only to a small propor-
tion of the broader population receiving naltrexone for opiate
dependence. In addition, it is important to note that extensive
clinical research demonstrates that methadone maintenance
produces superior outcomes to detoxification. Rapid detoxifi-
cation is not routinely available in Australia; transferring pa-
tients stabilized on methadone maintenance to rapid detoxifi-
cation or naltrexone treatment is not standard practice.
Nonetheless, many patients feel that methadone maintenance
is restrictive and desire more flexible treatment options.
Within this context, naltrexone may be an appropriate treat-
ment option for some patient groups.
The complexity of the relation between opiate-dependence
treatment and mood state is indicated by the different trajec-
tories for depression and anxiety. Anxiety showed an in-
crease over time; those receiving naltrexone tended to experi-
ence their increase soon after commencement of treatment,
whereas those on methadone reported their increase later.
Anxiety symptoms may have been related to detoxification
and naltrexone, given that those in the methadone condition
were offered detoxification at the end of their 6-month
follow-up, and those receiving naltrexone may have been
anxious early in the treatment period, because they had
started a new therapy. This is consistent with previous stud-
ies reporting high levels of anxiety both before and after
detoxification.34 The relation between anxiety symptoms and
lack of attendance at subsequent assessments indicates that
these changes may be clinically significant. The importance of
anxiety symptoms in predicting opioid-dependence treat-
ment outcomes has not been fully established and is a subject
for future research.
The timing of assessment may have influenced the obser-
vation of depressive or anxiety symptoms and may be one
factor contributing to contradictory reports of depressive
symptoms associated with naltrexone. Previous studies that
have linked naltrexone with depression typically assessed
symptoms of depression within 24 hours of exposure to a
single naltrexone dose16,17 or in the early stages (weeks 1 or
2) of ongoing treatment,17,18 in contrast to this study, which
did not assess depression between baseline and 1 month.
Although this is a limitation of the current study, assess-
ment of affective state soon after detoxification is difficult,
because negative affective states and affective lability are
frequently reported during opioid withdrawal.35–38 Even if
mood was assessed at earlier stages, it would have been dif-
ficult to establish whether the observed changes were attrib-
utable to naltrexone, opioid detoxification or nonspecific
factors. Nonetheless, it would be prudent to monitor de-
pression and anxiety symptoms in patients receiving nal-
trexone at regular stages throughout treatment.
Another factor that may have influenced the results relates
to the standard of care provided in each group. For example,
methadone doses used in the control group are low (mean
< 50 mg daily), and lower than doses reported to generate the
full benefits of methadone treatment.26 Many participants
anecdotally reported reducing their methadone dose before
study enrolment, based on the expectation that this would
make detoxification less challenging. However, this may
have influenced results, because depressive symptoms have
been associated with low methadone doses.39 Similarly, en-
gagement in psychotherapy may have affected depressive
symptoms. No specific psychotherapy was provided by this
study or routinely provided by the clinics involved; engage-
ment in psychotherapy remained the choice of the individ-
ual. A limitation of this study is that we were unable to fully
determine involvement in psychotherapy and its impact on
treatment outcome.
Depression scores were associated with social functioning
but not measures of heroin use. This is consistent with other
findings that suggest psychiatric symptoms may have a
greater impact on psychosocial outcomes than substance
use.40 This connection and those observed between depres-
sion, anxiety and craving may indicate that negative mood
states may act as a marker for patients requiring additional
support or psychological treatment. Similar associations have
been reported during naltrexone treatment for alcohol use.41
It is likely that the relation between mood and drug craving
is bidirectional: negative mood states may induce drug crav-
ing,42 and exposure to drug-related stimuli can increase both
craving and depressed mood.43
How do these findings influence clinical decision-making
regarding treatment selection for opioid dependence? It has
been well established that initiation of agonist treatments is
associated with improvements in mood.44,45 The capacity for
antagonist treatments to elicit a similar improvement in
psychological symptoms has not been convincingly demon-
strated. Nonetheless, in contrast to expectations, switching
from methadone maintenance to an antagonist-based treat-
ment was not accompanied by any discernible increase in
depression and may improve mood in patients fully en-
gaged or adherent to treatment. Rounsaville and col-
leagues44 suggest that the volume of treatment is more im-
portant in predicting changes in mood than the particular
treatment per se. The minor impact of naltrexone treatment
in improving mood may be secondary to poorer rates of
treatment engagement or adherence typically reported for
antagonist treatments. Within this context, depressive
symptoms need not be considered a contraindication for
naltrexone treatment. Whatever treatment is used, it re-
mains important to monitor individuals who are receiving
opioid-dependence treatments for depressive and anxiety
symptoms on a regular basis.46 The challenge for future re-
search will be to determine which individuals are at greater
risk of poorer mood outcomes and to identify effective in-
terventions for this group.
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